<DOC>
	<DOC>NCT00809848</DOC>
	<brief_summary>The study will evaluate the safety and efficacy of AGN-210669 ophthalmic solution in comparison with AGN-210669 vehicle and bimatoprost ophthalmic solution dosed once-daily each morning, in subjects with ocular hypertension or primary open-angle glaucoma. Subjects will be followed for 2 weeks.</brief_summary>
	<brief_title>Safety and Efficacy of AGN 210669 Ophthalmic Solution in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Bimatoprost</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Ocular hypertension or primary openangle glaucoma Females of nonchildbearing potential Subject requires IOPlowering therapy in both eyes IOP ≥ 22 mm Hg and ≤ 34 mm Hg Has a visual acuity score of 20/100 or better in each eye Uncontrolled systemic disease Active ocular disease Alteration of existing chronic systemic medications Known allergy or sensitivity to the study medications Ophthalmic corticosteroids Visual field loss which in the opinion of the investigator is functionally significant History of ocular laser, intraocular surgery, or refractive surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2013</verification_date>
</DOC>